Hubert Orfeuvre
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, COVID-19 Clinical Research Studies, Breast Cancer Treatment Studies, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial(2022)291 cited
- → Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)(2024)28 cited
- → Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study(2024)
- → Abstract P2-07-17: Palbociclib in women aged ≥70 years as first-line treatment for endocrine-sensitive Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative locally advanced or metastatic breast cancer: final results of PalomAGE(2025)